# Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

> **NCT05165394** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 93 (actual)

## Conditions studied

- Anhedonia
- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** NBI-1065846

## Key facts

- **NCT ID:** NCT05165394
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-09-13
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05165394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05165394, "Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05165394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*